July 18, 2013
Trinity International University, Deerfield, IL
With new prenatal screening technologies it is now possible to identify aneuploidies from cell-free DNA in maternal blood as early as 9 weeks. This means that with a simple test of a mother's blood, Down syndrome and other genetic conditions can be identified earlier and with nearly 100% accuracy.
It is more critical than ever that support structures are put into place which provide factual, balanced information and share the positive stories of delivering and raising children with Down syndrome and other genetic conditions.
An Overview of Prenatal Testing Methods, Their Accuracy, Availability, and Use
David Prentice, PhD. Senior Fellow and Director, Life Sciences, Family Research Council
The Relationship between Prenatal Diagnosis and Termination Rates: What is Known?
Peter J. Smith, MD, MA. Associate Professor, Department of Pediatrics, University of Chicago
Legislation and Policy Initiatives Regarding Prenatal Testing and Information
Mark W Leach, JD, MA (Bioethics), Member, Stites & Harbison PLLC. President, Down Syndrome of Louisville
Research into Therapeutic Treatments for Trisomy 21 and Other Genetic or Congenital Disabilities
Byron C. Calhoun, MD, FACOG, FACS. Professor and Vice-Chair in the Department of Obstetrics and Gynecology at West Virginia University-Charleston
Communicating an Unexpected Prenatal Diagnosis: Offering Comfort and Encouragement to Families
John M. Thorp, Jr., MD. Hugh McAllister Distinguished Professor of Obstetrics and Gynecology at the University of North Carolina at Chapel Hill. Donna Harrison, MD, Executive Director and Director of Research and Public Policy at American Association of Pro-Life Obstetricians and Gynecologists, presented Dr. Thorp's materials.
Organized and funded by:
The Jerome Lejeune Foundation, USA - Family Research Council - Medical Students for Life - The Center for Bioethics & Human Dignity
To request additional information:
contact@lejeuneusa.org
267-403-2910